ENTtoday
  • Home
  • Practice Focus
    • Allergy
    • Facial Plastic/Reconstructive
    • Head and Neck
    • Laryngology
    • Otology/Neurotology
    • Pediatric
    • Rhinology
    • Sleep Medicine
  • Departments
    • Issue Archive
    • TRIO Best Practices
      • Allergy
      • Facial Plastic/Reconstructive
      • Head and Neck
      • Laryngology
      • Otology/Neurotology
      • Pediatric
      • Rhinology
      • Sleep Medicine
    • Career Development
    • Case of the Month
    • Everyday Ethics
    • Health Policy
    • Legal Matters
    • Letter From the Editor
    • Medical Education
    • Online Exclusives
    • Practice Management
    • Resident Focus
    • Special Reports
    • Tech Talk
    • Viewpoint
    • What’s Your O.R. Playlist?
  • Literature Reviews
    • Allergy
    • Facial Plastic/Reconstructive
    • Head and Neck
    • Laryngology
    • Otology/Neurotology
    • Pediatric
    • Rhinology
    • Sleep Medicine
  • Multimedia
    • Video
    • Audio
  • Events
    • Featured Events
    • TRIO Meetings
  • Contact Us
    • About Us
    • Editorial Board
    • Triological Society
    • Advertising Staff
    • Subscribe
    • eNewsletters
  • Advertise
    • Place an Ad
    • Classifieds
    • Rate Card
  • Search

FDA Approves First Sublingual Allergy Immunotherapy Agents

by Cheryl Alkon • June 1, 2014

  • Tweet
  • Email
Print-Friendly Version

You might also like:

  • Sublingual Immunotherapy a Potential Treatment for Allergic Rhinitis
  • Sublingual Immunotherapy (SLIT) Quality of Life Outcomes
  • Old Problem, New Focus: Otolaryngologists tailor allergy treatments to geriatric patients
  • American Academy of Otolaryngic Allergy Focused on Advocacy, Patient Care
Explore this issue:
June 2014

In April, the U.S. Food and Drug Administration (FDA) approved three sublingual oral immunotherapy (SLIT) agents, the first to be approved in the United States.

Oralair, from GREER Laboratories, which is indicated for grass pollen-induced allergic rhinitis with or without conjunctivitis confirmed by positive skin test or in vitro testing for grass pollen-specific immunoglobulin E antibodies for any of five grass species (Sweet Vernal, Orchard, Perennial Rye, Timothy, and Kentucky Blue grasses), received FDA approval on April 1 of this year. Two weeks later, the FDA approved Merck’s Grastek, which treats those allergic to Timothy grass. And, just three days later, the FDA gave the go-ahead to Merck’s Ragwitek, a treatment for ragweed allergies.

These three medications are the first FDA-approved allergy treatments to be administered sublingually to help desensitize a patient to a particular allergen or group of allergens. In the U.S., an estimated 7.5 million people are allergic to Timothy and other grass pollens, while approximately 4.5 million people are allergic to short ragweed pollen.

How They Work

“This is a revolutionary change in the way the patient undergoes desensitization to allergens by providing immunotherapy, yet the effects of providing it appear to be essentially the same as injection therapy,” said Bradley Marple, MD, professor and vice chairman of the department of otolaryngology-head and neck surgery and an associate dean for graduate medical education at the University of Texas Southwestern Medical Center in Dallas. Dr. Marple is also a member of ENTtoday’s editorial advisory board.

Historically, allergy treatment has been a three-tiered process, said Dr. Marple. The first tier involves avoiding the allergen altogether, though some, like pollen, can be hard to hide from as the spring season unfolds. The second tier involves the use of nasal steroids, nasal irrigation, and antihistamines. If allergy symptoms persist, immunotherapy is recommended. “This translates into patients needing to be somewhat tethered to a physician’s office, and it’s kind of a hardship for patients who live removed from the office and who have busy schedules,” said Dr. Marple.

There’s also the fear factor. “Many patients do not pursue immunotherapy because some patients don’t like needles and are scared of shots,” said Nathan Sautter, MD, an assistant professor of otolaryngology at Oregon Health and Science University in Portland.

But with oral immunotherapy, the antigens are absorbed through the mucosa and then migrate through the lymphatic system and into the lymph nodes, where they works with the immune system to help desensitize the body to an allergen, said Dr. Marple. The patient only needs to be observed for potential anaphylaxis after the first pill is taken; if there’s no reaction, the patient can self-administer at home for the remainder of the treatment. The regimen typically starts 12 to 16 weeks before the grass/ragweed season begins and may continue for up to three years.

Pages: 1 2 3 Single Page

Filed Under: Allergy, Features, Practice Focus Tagged With: allergy, SLITIssue: June 2014

You might also like:

  • Sublingual Immunotherapy a Potential Treatment for Allergic Rhinitis
  • Sublingual Immunotherapy (SLIT) Quality of Life Outcomes
  • Old Problem, New Focus: Otolaryngologists tailor allergy treatments to geriatric patients
  • American Academy of Otolaryngic Allergy Focused on Advocacy, Patient Care

The Triological SocietyENTtoday is a publication of The Triological Society.

The Laryngoscope
Ensure you have all the latest research at your fingertips; Subscribe to The Laryngoscope today!

Laryngoscope Investigative Otolaryngology
Open access journal in otolaryngology – head and neck surgery is currently accepting submissions.

Classifieds

View the classified ads »

TRIO Best Practices

View the TRIO Best Practices »

Top Articles for Residents

  • How Writing Helps a Medical Resident Better Care for Patients
  • How Physicians Can Build a Network to Boost Their Career
  • How To Survive the First Year of Medical Residency
  • ACGME Revises Cap on Resident Work Hours
  • Ethical Implications of Burnout in Otolaryngology Residents
  • Popular this Week
  • Most Popular
  • Most Recent
    • Vertigo in the Elderly: What Does It Mean?
    • New Developments in the Management of Eustachian Tube Dysfunction
    • Is There a Crisis in the Otolaryngology Match?
    • Some Laryngopharyngeal Reflux Resists PPI Treatment
    • Weaning Patients Off of PPIs
    • New Developments in the Management of Eustachian Tube Dysfunction
    • Vertigo in the Elderly: What Does It Mean?
    • Eustachian Tuboplasty: A Potential New Option for Chronic Tube Dysfunction and Patulous Disease
    • Some Laryngopharyngeal Reflux Resists PPI Treatment
    • Short-and Long-Term Data Suggest Efficacy of Turbinate Ablation
    • Counseling Patients on Safe Nasal Irrigation
    • Artificial Intelligence and Machine Learning in Otolaryngology
    • Letter from the Editor: Peer Reviewing Sensational Headlines
    • Is Topical Epinephrine Safe for Hemostasis in Endoscopic Sinus Surgery?
    • Is it Safe to Kiss in Era of HPV Head and Neck Cancer ‘Epidemic’?

Polls

Is artificial intelligence an advantage for medicine?

View Results

Loading ... Loading ...
  • Polls Archive
  • Home
  • Contact Us
  • Advertise
  • Privacy Policy

Visit: The Triological Society • The Laryngoscope • Triological Meeting Posters

Wiley
© 2019 The Triological Society. All Rights Reserved.
ISSN 1559-4939

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.